Sotera Health (NASDAQ:SHC) Upgraded at Zacks Research

Zacks Research upgraded shares of Sotera Health (NASDAQ:SHC) from a hold rating to a strong-buy rating in a research note published on Thursday morning,Zacks.com reports.

Several other brokerages also recently weighed in on SHC. Piper Sandler boosted their price objective on shares of Sotera Health from $15.00 to $17.00 and gave the stock a “neutral” rating in a research report on Wednesday, November 5th. Barclays boosted their price target on shares of Sotera Health from $19.00 to $20.00 and gave the company an “overweight” rating in a research report on Wednesday, November 5th. BMO Capital Markets started coverage on Sotera Health in a report on Thursday, November 13th. They set an “outperform” rating and a $19.00 price objective on the stock. William Blair assumed coverage on Sotera Health in a report on Thursday, December 18th. They issued an “outperform” rating for the company. Finally, JPMorgan Chase & Co. upped their target price on Sotera Health from $14.00 to $16.00 and gave the company a “neutral” rating in a research report on Wednesday, November 5th. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $17.80.

Sotera Health Stock Performance

NASDAQ:SHC opened at $17.69 on Thursday. Sotera Health has a 12 month low of $9.53 and a 12 month high of $17.94. The company has a debt-to-equity ratio of 4.04, a current ratio of 2.38 and a quick ratio of 2.18. The firm has a market capitalization of $5.03 billion, a PE ratio of 93.11 and a beta of 1.82. The business’s fifty day moving average price is $16.74 and its 200 day moving average price is $15.08.

Sotera Health (NASDAQ:SHC) last issued its earnings results on Tuesday, November 4th. The company reported $0.26 earnings per share for the quarter, topping the consensus estimate of $0.22 by $0.04. The business had revenue of $311.31 million for the quarter, compared to analyst estimates of $303.63 million. Sotera Health had a return on equity of 43.69% and a net margin of 4.82%.Sotera Health has set its FY 2025 guidance at 0.810-0.860 EPS. On average, sell-side analysts anticipate that Sotera Health will post 0.61 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director Pincus & Co. Warburg sold 9,720,000 shares of the business’s stock in a transaction dated Wednesday, December 3rd. The stock was sold at an average price of $16.33, for a total value of $158,727,600.00. Following the transaction, the director owned 34,102,952 shares in the company, valued at $556,901,206.16. The trade was a 22.18% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Gtcr Investment Xi Llc sold 12,000,000 shares of the stock in a transaction that occurred on Monday, November 10th. The stock was sold at an average price of $15.65, for a total value of $187,800,000.00. Following the sale, the director directly owned 29,215,301 shares of the company’s stock, valued at $457,219,460.65. The trade was a 29.12% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 29,384,104 shares of company stock valued at $471,824,511 over the last quarter. 47.55% of the stock is currently owned by insiders.

Institutional Trading of Sotera Health

A number of institutional investors have recently modified their holdings of SHC. Versant Capital Management Inc grew its holdings in Sotera Health by 117.6% during the third quarter. Versant Capital Management Inc now owns 2,535 shares of the company’s stock worth $40,000 after acquiring an additional 1,370 shares during the period. UMB Bank n.a. grew its stake in shares of Sotera Health by 112.8% during the 2nd quarter. UMB Bank n.a. now owns 2,635 shares of the company’s stock worth $29,000 after purchasing an additional 1,397 shares during the period. EverSource Wealth Advisors LLC grew its stake in shares of Sotera Health by 831.4% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 3,288 shares of the company’s stock worth $37,000 after purchasing an additional 2,935 shares during the period. Parallel Advisors LLC increased its holdings in shares of Sotera Health by 124.0% in the 2nd quarter. Parallel Advisors LLC now owns 3,340 shares of the company’s stock valued at $37,000 after purchasing an additional 1,849 shares in the last quarter. Finally, Caitong International Asset Management Co. Ltd lifted its stake in shares of Sotera Health by 33.1% in the second quarter. Caitong International Asset Management Co. Ltd now owns 3,583 shares of the company’s stock valued at $40,000 after purchasing an additional 892 shares during the period. 91.03% of the stock is currently owned by hedge funds and other institutional investors.

Sotera Health Company Profile

Sotera Health Inc (NASDAQ: SHC) is a global provider of sterilization and laboratory testing services that support the medical device, pharmaceutical, life sciences and consumer product industries. Headquartered in Jacksonville, Florida, the company offers a suite of services designed to ensure products meet rigorous safety and regulatory requirements before reaching market.

Sotera Health operates through three primary service platforms. Its Sterigenics division delivers contract sterilization solutions, including ethylene oxide (EtO), gamma irradiation, electron beam and X-ray technologies.